Apply now for the Venture Challenge Spring 2025!
The winter edition of the Venture Challenge will take place on 27, 28 and 29 November at Pivot Park. This marks the third edition of 2024 hosted at Pivot Park. We can’t wait to see what the startups in this edition will bring to the table.
Boehringer Ingelheim and Synaffix B.V., announced that Boehringer has licensed Synaffix’s ADC technology. This new partnership significantly bolsters Boehringer’s ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with cancer.
Elevation Oncology licenses ADC Technology from Synaffix to drive pipeline expansion
Synaffix B.V. today announces that it has entered into a licensing agreement with Elevation Oncology, Inc., an innovative oncology company dedicated to the discovery and development of selective cancer therapies designed to treat patients with a range of solid tumours that have significant unmet medical needs.
Citryll Raises EUR 85 Million Series B
Citryll Raises EUR 85 Million Series B to Advance Novel NET-Targeting Therapy for Immune-Mediated Inflammatory Disorders
Synaffix licenses metal-free click chemistry technology to Illumina
Synaffix announces it has entered into a licensing agreement with Illumina, a global leader in DNA sequencing and array-based technologies. The agreement grants Illumina access to Synaffix’s patented metal-free click chemistry, for next-generation DNA sequencing applications.
Ardena’s Nanomedicine Facility secures full GMP approval for manufacturing
Ardena has announced a significant milestone with its state-of-the-art nanomedicine facility at Pivot Park receiving full Good Manufacturing Practice (GMP) approval from the Dutch Healthcare Authority.
STANT: New Biotech Company at Pivot Park
STANT, a new Dutch company based at the Pivot Park in Oss, is developing proprietary inhibitors of the STING pathway with a unique and differentiated mechanism of action.
RIBOPRO Secures Series A Funding to Accelerate mRNA-Based technologies
RIBOPRO has successfully closed a Series A funding round. This funding will drive efforts to transform the industry with innovative mRNA and LNP technologies, providing a range of solutions to address current challenges within the field.
Synaffix licenses ADC technology to BigHat Biosciences
Synaffix BV announces that it has licensed its ADC technology to BigHat Biosciences. BigHat will combine Synaffix technology with its world-class machine learning antibody design platform for the development of a new ADC pipeline programme.
PharmSupport rebrands as Biolumnis
PharmSupport has announced a significant milestone today with a complete rebranding, unveiling its new name: Biolumnis. Alongside the name change, the company has launched a revamped website, marking the beginning of an exciting new era.
Ardena expands bioanalytical services in Europe
Ardena is strengthening its bioanalytical services with a new laboratory and investments in Europe.
Dennis Löwik: New lector Drug Discovery at Pivot Park
Dennis Löwik is the new Drug Discovery lecturer at Pivot Park, aiming to boost research with AI and foster industry collaborations. He aims to expand the lectureship in terms of people and research in the coming years.
or call
Pivot Park – Building RK
Kloosterstraat 9
5349 AB Oss
The Netherlands
+31 (0)412 – 84 60 10
info@pivotpark.com
Pivot Park Exploitatie B.V.
Building OP
Kloosterstraat 9
5349 AB Oss
The Netherlands
10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.
We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.
The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.
Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.
This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.
We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.
Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.
